NCT06631326View on ClinicalTrials.gov

HAIC in Combination with PD-1 Inhibitors and Lenvatinib for High Tumor Burden Advanced HCC (CHANCE2416)

RecruitingOBSERVATIONAL
Enrollment

228

Participants

Timeline

Start Date

September 16, 2024

Primary Completion Date

September 30, 2025

Study Completion Date

December 30, 2025

Conditions
HCC - Hepatocellular CarcinomaHepatic Arterial Infusion ChemotherapyBCLC Stage C Hepatocellular CarcinomaLenvatinibPD-1 Inhibitors
Interventions
PROCEDURE

hepatic artery infusion chemotherapy

Hepatic arterial infusion chemotherapy including FOLFOX and RALOX

DRUG

Lenvatinib + PD-1 monoclonal antibody

PD-1 inhibitors including Camrelizumab, Sintilimab, Tislelizumab

Trial Locations (1)

110000

RECRUITING

The first hospital of China medical university, Shenyang

All Listed Sponsors
lead

First Hospital of China Medical University

OTHER